NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/e7Vus With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of human afflictions, including neurological disorders (e.g., Alzheimer's and Parkinson's), cardiovascular conditions (e.g., heart disease, high blood pressure, atherosclerotic plaques, inflammation), cancer, autoimmune disease (e.g., Crohn’s), and many new possibilities; studies are investigating the efficacy of GLP-1 drugs on kidney disease, liver disease, bone health and even aging.

2024年1月11日，纽约（环球通讯社）——NetworkNewsAudio–Lexaria Bioscience Corp.（纳斯达克：LEXX）宣布推出一个名为“GLP-1糖尿病、减肥药可能带来的令人兴奋的新疗法”的广播节目。要听音频新闻稿，请访问：NetworkNewsAudio新闻播客要查看完整的社论，请访问：https://nnw.fm/e7Vus随着每一项新的研究，GLP-1治疗潜力的范围不断扩大，描绘了一幅充满活力的未来图景，其中一个分子可以解决多种人类疾病，包括神经系统疾病（例如阿尔茨海默氏症和帕金森氏症），心血管疾病（例如心脏病，高血压，动脉粥样硬化斑块，炎症），癌症，自身免疫性疾病（例如克罗恩病）和许多新的可能性；研究正在调查GLP-1药物对肾脏疾病，肝脏疾病，骨骼健康甚至衰老的疗效。

With so many proven and potential blockbuster indications, enhanced delivery and increased efficacy would supercharge the impact of GLP-1 agonists. Lexaria Bioscience Corp. (NASDAQ: LEXX) intends to do just that with its patented DehydraTECH platform developed to improve the way active molecules enter the bloodstream upon oral ingestion.

有了如此多已被证实和潜在的大片适应症，增强的递送和增加的功效将增强GLP-1激动剂的影响。Lexaria Bioscience Corp.（纳斯达克：LEXX）打算通过其专利的脱水技术平台来实现这一目标，该平台旨在改善活性分子在口服摄入后进入血流的方式。

DehydraTECH has demonstrated enhanced delivery of certain active molecules into brain tissue, which has particular importance for centrally active compounds via oral administration. Lexaria has also developed DehydraTECH formulations for other applications demonstrating superior bioabsorption when administered intraorally (sublingual or tissues of the mouth).                        About Lexaria Bioscience Corp.

脱水技术已经证明某些活性分子向脑组织的传递增强，这对于通过口服给药的中枢活性化合物特别重要。Lexaria还开发了用于其他应用的脱水制剂，当口服（舌下或口腔组织）时表现出优异的生物吸收。关于Lexaria Bioscience Corp。

Lexaria’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) ente.

Lexaria的专利药物输送技术Deterhetech（TM）改进了活性药物成分（API）的回收方式。